https://www.selleckchem.com/pr....oducts/dir-cy7-dic18
hemangiopericytomas. Long-term close clinical and imaging follow-up is also necessary.Background The survival benefits of regorafenib (REG) and trifluridine/tipiracil hydrochloride (TFTD) have been demonstrated in chemorefractory patients with metastatic colorectal cancer (mCRC). However, the effects of crossover administration of REG and TFTD on patient survival remain unclear. The present study evaluated the association between exposure to REG and TFTD and overall survival (OS) in patients with mCRC using data from the REGOTAS s
Like
Comment
Share
